Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia

Journal of Experimental Medicine

Volumn 207, Issue 13, 2010, Pages 2785-2792

  El Hajj, Hiba ^a   El Sabban, Marwan ^a   Hasegawa, Hideki ^b,c   Zaatari, Ghazi ^a   Ablain, Julien ^d   Saab, Shahrazad T ^a   Janin, Anne ^e   Mahfouz, Rami ^a   Nasr, Rihab ^a   Kfoury, Youmna ^a   Nicot, Christophe ^f,g,h   Hermine, Olivier ⁱ   Hall, William ^c   De Thé, Hugues ^d   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d Institut Universitaire d'Hématologie   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; PROTEASOME; RECOMBINANT ALPHA2A INTERFERON; TAX PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; ENGRAFTMENT; HUMAN T CELL LEUKEMIA VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECIPIENT; T CELL LEUKEMIA; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; CELL CYCLE; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IN SITU NICK-END LABELING; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, SCID; MICE, TRANSGENIC; ORGAN SIZE; OXIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TREATMENT OUTCOME;

EID: 78650373635     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20101095     Document Type: Article

References (30)

1. Asquith, B., E. Hanon, G.P. Taylor, and C.R. Bangham. 2000. Is human T-cell lymphotropic virus type I really silent? Philos. Trans. R. Soc. Lond. B Biol. Sci. 355:1013-1019. doi:10.1098/rstb.2000.0638
2. Banerjee, P., A. Tripp, M.D. Lairmore, L. Crawford, M. Sieburg, J.C. Ramos, W. Harrington Jr., M.A. Beilke, and G. Feuer. 2010. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood. 115:2640-2648. doi:10.1182/blood-2009-10-246959
3. Bazarbachi, A., M.E. El-Sabban, R. Nasr, F. Quignon, C. Awaraji, J. Kersual, L. Dianoux, Y. Zermati, J.H. Haidar, O. Hermine, and H. de Thé. 1999. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 93:278-283.
4. Bazarbachi, A., D. Ghez, Y. Lepelletier, R. Nasr, H. de Thé, M.E. El-Sabban, and O. Hermine. 2004. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 5:664-672. doi:10.1016/S1470-2045(04)01608-0 (Pubitemid 40267851)
5. Dick, J.E. 2008. Stem cell concepts renew cancer research. Blood. 112:4793-4807. doi:10.1182/blood-2008-08-077941
6. Downing, J.R. 2003. The core-binding factor leukemias: lessons learned from murine models. Curr. Opin. Genet. Dev. 13:48-54. doi:10.1016/S0959-437X(02) 00018-7 (Pubitemid 36143927)
7. El-Sabban, M.E., R. Nasr, G. Dbaibo, O. Hermine, N. Abboushi, F. Quignon, J.C. Ameisen, F. Bex, H. de Thé, and A. Bazarbachi. 2000. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 96:2849-2855.
8. Essers, M.A., S. Offner, W.E. Blanco-Bose, Z. Waibler, U. Kalinke, M.A. Duchosal, and A. Trumpp. 2009. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 458:904-908. doi:10.1038/nature07815
9. Faber, J., and S.A. Armstrong. 2007. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res. 67:8425-8428. doi:10.1158/0008-5472.CAN-07-0972 (Pubitemid 47437412)
10. Gill, P.S., W. Harrington Jr., M.H. Kaplan, R.C. Ribeiro, J.M. Bennett, H.A. Liebman, M. Bernstein-Singer, B.M. Espina, L. Cabral, S. Allen, et al. 1995. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 332:1744-1748. doi:10.1056/NEJM199506293322603
11. Hasegawa, H., H. Sawa, M.J. Lewis, Y. Orba, N. Sheehy, Y. Yamamoto, T. Ichinohe, Y. Tsunetsugu-Yokota, H. Katano, H. Takahashi, et al. 2006. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat. Med. 12:466-472. doi:10.1038/nm1389
12. Hermine, O., D. Bouscary, A. Gessain, P. Turlure, V. Leblond, N. Franck, A. Buzyn-Veil, B. Rio, E. Macintyre, F. Dreyfus, et al. 1995. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332:1749-1751. doi:10.1056/NEJM199506293322604
13. Hermine, O., H. Dombret, J. Poupon, B. Arnulf, F. Lefrère, P. Rousselot, G. Damaj, R. Delarue, J.P. Fermand, J.C. Brouet, et al. 2004. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. 5:130-134. doi:10.1038/sj.thj.6200374 (Pubitemid 38519262)
14. Hu, J., Y.F. Liu, C.F. Wu, F. Xu, Z.X. Shen, Y.M. Zhu, J.M. Li, W. Tang, W.L. Zhao, W. Wu, et al. 2009. Long-term efficacy and safety of alltrans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 106:3342-3347. doi:10.1073/pnas.0813280106
15. Ishitsuka, K., J. Suzumiya, M. Aoki, K. Ogata, S. Hara, and K. Tamura. 2007. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 92:719-720. doi:10.3324/haematol.10703 (Pubitemid 350144285)
16. Ito, K., R. Bernardi, A. Morotti, S. Matsuoka, G. Saglio, Y. Ikeda, J. Rosenblatt, D.E. Avigan, J. Teruya-Feldstein, and P.P. Pandolfi. 2008. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 453:1072-1078. doi:10.1038/nature07016 (Pubitemid 351871736)
17. Kchour, G., M. Tarhini, M.M. Kooshyar, H. El Hajj, E. Wattel, M. Mahmoudi, H. Hatoum, H. Rahimi, M. Maleki, H. Rafatpanah, et al. 2009. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 113:6528-6532. doi: 10.1182/blood-2009-03-211821
18. Kelly, P.N., A. Dakic, J.M. Adams, S.L. Nutt, and A. Strasser. 2007. Tumor growth need not be driven by rare cancer stem cells. Science. 317:337. doi:10.1126/science.1142596 (Pubitemid 47106366)
19. Kogan, S.C. 2009. Curing APL: differentiation or destruction? Cancer Cell. 15:7-8. doi:10.1016/j.ccr.2008.12.012
20. 3-induced PML or PML/retinoic acid receptor α degradation. J. Exp. Med. 193:1361-1371. doi:10.1084/jem.193.12.1361 (Pubitemid 32565965)
21. Lallemand-Breitenbach, V., M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou, J. Zhu, B. Raught, and H. de Thé. 2008. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10:547-555.doi:10.1038/ncb1717 (Pubitemid 351627374)
22. Lavau, C., R.T. Luo, C. Du, and M.J. Thirman. 2000. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc. Natl. Acad. Sci. USA. 97:10984-10989. doi:10.1073/pnas.190167297
23. Matsuoka, M., and K.T. Jeang. 2007. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer. 7:270-280. doi:10.1038/nrc2111 (Pubitemid 46480972)
24. Nasr, R., A. Rosenwald, M.E. El-Sabban, B. Arnulf, P. Zalloua, Y. Lepelletier, F. Bex, O. Hermine, L. Staudt, H. de Thé, and A. Bazarbachi. 2003. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 101:4576-4582. doi:10.1182/blood-2002-09-2986 (Pubitemid 36857830)
25. Nasr, R., E. Chiari, M. El-Sabban, R. Mahieux, Y. Kfoury, M. Abdulhay, V. Yazbeck, O. Hermine, H. de Thé, C. Pique, and A. Bazarbachi. 2006. Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. Blood. 107:4021-4029. doi:10.1182/blood-2005-09-3572 (Pubitemid 43726810)
26. Nasr, R., M.C. Guillemin, O. Ferhi, H. Soilihi, L. Peres, C. Berthier, P. Rousselot, M. Robledo-Sarmiento, V. Lallemand-Breitenbach, B. Gourmel, et al. 2008. Eradication of acute promyelocytic leukemiainitiating cells through PML-RARA degradation. Nat. Med. 14:1333-1342. doi:10.1038/nm.1891
27. Portis, T., J.C. Harding, and L. Ratner. 2001. The contribution of NFkappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood. 98:1200-1208. doi:10.1182/blood.V98.4.1200
28. Quintana, E., M. Shackleton, M.S. Sabel, D.R. Fullen, T.M. Johnson, and S.J. Morrison. 2008. Efficient tumour formation by single human melanoma cells. Nature. 456:593-598. doi:10.1038/nature07567
29. Stadler, M., M.K. Chelbi-Alix, M.H.M. Koken, L. Venturini, C. Lee, A. Saïb, F. Quignon, L. Pelicano, M.-C. Guillemin, C. Schindler, and H. de Thé. 1995. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene. 11:2565-2573. (Pubitemid 26023824)
30. Zhu, J., M.H.M. Koken, F. Quignon, M.K. Chelbi-Alix, L. Degos, Z.Y. Wang, Z. Chen, and H. de Thé. 1997. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:3978-3983. doi:10.1073/pnas.94.8.3978 (Pubitemid 27180484)